Markets

Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT

Sep 11, 2026 · 04:02 PM ET· updated 2h ago

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call

Why It Matters

Corbus is sharing results from a big obesity medicine test on Monday morning. When companies announce test results, you watch how well the medicine worked to understand if the company is making progress.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CRBP10.26

+2.02 (+24.45%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.